University of California San Diego, La Jolla, CA [email protected]
Dr. Loomba reports receiving consulting fees from Alnylam–Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Galmed Pharmaceuticals, Intercept Pharmaceuticals, Ionis Pharmaceuticals, Janssen, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, and Theratechnologies, fees for serving as an advisory board member from 89Bio, CohBar, Galmed Pharmaceuticals, Gilead Sciences, Glympse Bio, Inipharm, Intercept Pharmaceuticals, Sagimet Biosciences, and Viking Therapeutics, being an employee of Liponexus, and receiving grant support, paid to his institution, from Allergan, Boehringer Ingelheim, Bristol Myers Squibb, Cirius, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, General Electric, Genfit, Gilead Sciences, Grail, Intercept Pharmaceuticals, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt Sciences, Pfizer, pH Pharma, Prometheus Laboratory, and Siemens; and Dr. Insel, receiving consulting fees from Merck and CuraSen Therapeutics and grant support from Pfizer and Bristol Myers Squibb. No other potential conflict of interest relevant to this letter was reported.
This letter was published on October 27, 2020, at NEJM.org.
